Zealand Pharma A/S (ZEAL.CO)

DKK 802.5

(0.44%)

Total Liabilities Summary of Zealand Pharma A/S

  • Zealand Pharma A/S's latest annual total liabilities in 2023 was 1.6 Billion DKK , up 121.86% from previous year.
  • Zealand Pharma A/S's latest quarterly total liabilities in 2024 Q2 was 759.5 Million DKK , up 1.42% from previous quarter.
  • Zealand Pharma A/S reported annual total liabilities of 723.89 Million DKK in 2022, down -36.49% from previous year.
  • Zealand Pharma A/S reported annual total liabilities of 1.13 Billion DKK in 2021, up 52.48% from previous year.
  • Zealand Pharma A/S reported quarterly total liabilities of 748.84 Million DKK for 2024 Q1, down -53.37% from previous quarter.
  • Zealand Pharma A/S reported quarterly total liabilities of 1.6 Billion DKK for 2023 FY, up 121.86% from previous quarter.

Annual Total Liabilities Chart of Zealand Pharma A/S (2023 - 2007)

Historical Annual Total Liabilities of Zealand Pharma A/S (2023 - 2007)

Year Total Liabilities Total Liabilities Growth
2023 1.6 Billion DKK 121.86%
2022 723.89 Million DKK -36.49%
2021 1.13 Billion DKK 52.48%
2020 747.52 Million DKK 109.48%
2019 356.84 Million DKK 214.35%
2018 113.51 Million DKK -45.63%
2017 208.77 Million DKK -49.87%
2016 416.43 Million DKK 8.88%
2015 382.45 Million DKK 11.2%
2014 343.92 Million DKK 1017.67%
2013 30.77 Million DKK 2.68%
2012 29.96 Million DKK 6.71%
2011 28.08 Million DKK -35.35%
2010 43.44 Million DKK 68.67%
2009 25.75 Million DKK 55.06%
2008 16.61 Million DKK -20.92%
2007 21 Million DKK 0.0%

Peer Total Liabilities Comparison of Zealand Pharma A/S

Name Total Liabilities Total Liabilities Difference
ALK-Abelló A/S 2.27 Billion DKK 29.529%
Bavarian Nordic A/S 4.01 Billion DKK 59.982%
Genmab A/S 3.67 Billion DKK 56.346%
Gubra A/S 145.62 Million DKK -1002.886%
Novo Nordisk A/S 207.92 Billion DKK 99.228%
Orphazyme A/S 5.07 Million DKK -31577.199%
Pharma Equity Group A/S 42.4 Million DKK -3687.459%